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Abstract
Malaria in the United States is rare and most commonly presents among returning travelers from endemic
areas. Diagnosis is classically dependent on a positive blood smear or polymerase chain reaction (PCR) test.
The objective of this case report is to highlight a case of suspected malaria in a high-risk individual with
negative diagnostic testing where a trial of empiric treatment was initiated based on clinical presentation
after a thorough discussion of risks and benefits. However, empiric treatment based on a single case is
limiting. We present a case of a 56-year-old man with extensive travel history throughout Asia, who
presented after multiple episodes of unprovoked 24-hour fevers over the past seven years. A thorough
rheumatologic and infectious inpatient workup was negative and oncology was consulted with low suspicion
for malignancy. However, based on clinical presentation and history, malaria remained highly suspected and
an empiric trial of anti-malarial treatment was initiated. One year after receiving treatment, the patient has
not experienced any further febrile episodes. The efficacy of blood smears and PCR may be influenced by the
malarial strain, as some species have low circulating biomass. Therefore, blood smears and PCR testing may
not always be diagnostic. Clinical signs supportive of a malarial infection include fever, rigors, chills,
hepato/splenomegaly, hyperbilirubinemia, and thrombocytopenia. Malaria is endemic to many regions
outside of Africa, including Asia, and should be considered in any returning traveler with recurrent fevers.
Categories: Internal Medicine, Pathology, Infectious Disease
Keywords: malaria, diagnostic accuracy, travel medicine, vivax infections, undiagnosed fever
Introduction
Globally, malaria is a common cause of recurring fevers and is recognized to have high endemicity in sub-
Saharan Africa and parts of Asia. However, malaria is also common outside of Africa and presents similarly
but has distinct clinical differences. Blood smears with Giemsa stain are the gold standard for diagnosis [1].
However, some species of Plasmodium are less detectable in peripheral blood, and negative blood smears do
not rule out the diagnosis [2,3].
Case Presentation
A 56-year-old man presented to the emergency department (ED) after experiencing a fever to 101°F (38.3°C)
at home. His past medical history included intermittent febrile episodes over the past seven years and
hypertension. His only medication was hydrochlorothiazide.
He experienced recurrent unprovoked febrile episodes (occurring every two to three months) for the past
seven years. These episodes were acute in onset, without preference for day or night, and followed a
stereotypic pattern. They began with chills/rigors followed by high-grade fever, severe day/nighttime
diaphoresis, nausea, and sometimes palpitations. Spontaneous resolution typically occurred within 24-48
hours and left him feeling severely fatigued the following day. The highest fever he recorded during an
episode was 104.1°F (40.1°C). He denied vomiting, diarrhea, abdominal pain, dysuria, arthralgias, myalgias,
or unexpected weight loss in association with these episodes. Between episodes, he felt completely
asymptomatic.
Five years prior to presentation, the patient resided in China for seven years. He also endorsed travel history
to Taiwan, Malaysia, Thailand, Philippines, Korea, Japan, Costa Rica, and the Dominican Republic. He
reports taking appropriate preventive measures against mosquitoes such as barriers and chemical
prophylaxis while traveling. His first febrile episode occurred in Taiwan within the seven-year period when
he was residing in China. Initially, after returning from China, he experienced dyspnea and chest pain with a
negative cardiac and pulmonary workup.
He did not endorse any illicit drug use, tobacco use, and seldomly consumed alcohol. He was up to date with
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sister. There was no other history of autoimmune disease or familial fever syndromes in his family.
The patient was admitted for systemic inflammatory response syndrome (SIRS) and for a diagnostic
assessment for fever of unknown origin. Diagnostic labs and imaging are summarized in Table 1 and Table 2,
respectively. Many of these were repeated during periods of fever without a significant difference in
results. An extensive rheumatologic and infectious workup was negative and oncology was consulted with
low suspicion for malignancy. The infectious disease service was consulted and reported concern for malaria
(particularly Plasmodium vivax (P. vivax) and Plasmodium ovale (P. ovale)) and brucellosis due to his travel
history, although there lacked typical periodicity. They noted that splenomegaly, anemia,
thrombocytopenia, and mild transaminitis seemed consistent with malaria. A malaria expert was consulted
at the Centers for Disease Control and recommended empiric treatment for malaria based on the patient’s
history and clinical findings. Following a negative glucose-6-phosphate dehydrogenase (G6PD) deficiency
screen, the patient was started on empiric treatment with oral atovaquone/proguanil 1000/400 mg for three
days and primaquine 30 mg daily for 14 days.
Lab Measured value Reference range
High sensitivity troponin < 6 (N) < 19 ng/L
D-dimer 434 (H) < 204 ng/mL
International normalized ratio (INR) 1.23 (N) 0.8-1.19
Prothrombin time (PT) 13.6 (H) 8.9-13.1 sec
Partial thromboplastin time (PTT) 24 (N) 24-35 sec
Urinalysis Unremarkable  
Urine drug screen Negative  
Urine culture Negative  
White blood cell 7.6 (N) 4.0-11.0 B/L
Neutrophil 91.40%  
Lymphocytes 5.00%  
Monocytes 2.90%  
Eosinophils 0.30%  
Basophils 0.10%  
Red blood cell 4.13 (L) 4.5-6 T/L
Hemoglobin 13.3 (L) 14-17 g/dL
Platelet 115 (L) 140-400 B/L
Blood cultures Negative  
Blood smear Unremarkable  
Lactate 2.6 (H) 0.5 - 2.0 mmol/L
C-reactive protein 0.30 (N) ≤ 0.80 mg/dL
Erythrocyte sedimentation rate 3 (N) 0-20
Thyroid stimulating hormone 1.31 (N) 0.3-5.00 uIU/mL
Lactate dehydrogenase 162 (H) 125-240 IU/L
Haptoglobin 75 (N) 16-200 mg/dL
Total bilirubin 1.3 (H) 1-1.2 mg/dL
Aspartate aminotransferase 45 (H) 0-40 IU/L
Alanine aminotransferase 76 (H) 0-44 IU/L
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Alkaline phosphatase 56 (N) 39-117 IU/L
Iron 28 (L) 55-160 mcg/dL
Total iron binding capacity 247 (L) 250-400 mcg/dL
Iron saturation 11% (L) 20-55%
Ferritin 839 (H) 30-40 ng/mL
Anti Smith Antibody 8 0 - 89 U/ml
Anti SS-A Antibody 19 0 - 91 U/ml
Anti SS-B Antibody 1 0 - 73 U/ml
ANA screen Negative  
Anti dsDNA Antibody 5 0 - 40 IU
Rheumatoid Factors 11 <14 IU/mL
A. phagocytoph. IgG <1:64 <1:64
A. phagocytoph. IgM <1:20 <1:20
Ehrlichia chaffeensis IgG <1:64 <1:64
Malaria Antigen Screen Presumptive Negative  
Lyme Ab screen 1.75 (equivocal) <0.90 Index
Lyme Disease Ab (IgM) Negative  
Lyme Disease Ab (IgG) Negative  
Syphilis Antibody Negative  
Quantiferon Result Negative  
Tuberculosis Antigen ≤ 0.000  
Hep B Surf Antigen Non-reactive  
Hep C Antibody Non-reactive  
HIV Ab/Ag Result Non-reactive  
Cytomegalovirus polymerase chain reaction (PCR), Plasma <100 IU/mL <100 IU/mL
Ebstein-Barr virus quantitative PCR, Plasma Non detected  
Mono Screen Non-reactive  
Babesia microti DNA reverse transcriptase-PCR Not detected  
Babesia microti DNA PCR Not detected  
TABLE 1: Blood tests
Rheumatologic workup was negative for anti-Smith antibody, anti-SS-A antibody, anti-SS-B antibody, antinuclear antibodies (ANA), anti-dsDNA antibody,
and rheumatoid factor. Infectious workup was negative for anaplasmosis, babesiosis, erlichiosis, malaria, Lyme, syphilis, tuberculosis, hepatitis B, hepatitis
C, HIV, cytomegalovirus (CMV), and Epstein-Barr virus (EBV).
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Imaging Findings
Chest X-ray Unremarkable
Computed tomography (CT) angiography of
pulmonary embolism (PE)
Negative for PE, mild interlobular interstitial thickening possibly representing pulmonary edema.
Cardiac morphology and pericardium were unremarkable.
CT abdomen pelvis
Mild splenomegaly measuring 16 x 12 cm, trace amounts of free fluid in the lower pelvis of uncertain
etiology, and an enlarged lymph node near the liver.
TABLE 2: Imaging findings
Three weeks following discharge, the patient was seen for outpatient follow-up. The anemia was resolving
with a hemoglobin of 13.3 g/dL; thrombocytopenia fully resolved with a platelet count of 169 B/L. Mild
transaminitis persisted (aspartate aminotransferase (AST) 42 IU/L, alanine aminotransferase (ALT) 64 IU/L),
total bilirubin had returned to normal (0.7 mg/dL), and alkaline phosphatase
(ALP) remained normal at 58 IU/L. Though the improvement in labs may have simply reflected the
resolution of SIRS, the patient reported no additional fevers during a telehealth follow-up one year later.
Discussion
The most common causes of recurrent febrile episodes include infectious, rheumatologic, and oncologic
etiologies. Oncology did not suspect malignancy as the febrile episodes were too far inconsistent, complete
blood cell count (CBC) and smear were normal, and the patient was up to date on cancer screening without a
high-risk family history. Rheumatology had low suspicion for an autoinflammatory disorder as the patient
had a lack of arthralgias and rash, was completely asymptomatic between episodes, and workup for common
autoimmune disorders were negative. Finally, workup for common infectious etiologies including viral,
bacterial, and parasitic were negative. Despite this, based on the patient's travel history and clinical
presentation, malaria was still highly suspected [4].
There are five Plasmodium species known to infect humans: falciparum, malariae, ovale, vivax, and knowlesi
[1]. Plasmodium falciparum (P. falciparum) is the most common, accounting for 99% of known malaria cases,
and generally is geographically-limited to sub-Saharan Africa [2,5]. P. vivax is the most common species
outside of Africa and accounts for 50% of non-African cases in the Americas, Eastern Mediterranean region,
and Asia [2,5]. In Asia, the burden of P. vivax has been reported to be as high as 80% of the total global
burden [4]. Other species in this region include Plasmodium knowlesi, P. ovale, and Plasmodium malariae [2,6].
Due to the infrequency of febrile episodes in this case, a Plasmodium species capable of producing
hypnozoites seems most likely. Only P. vivax is confirmed to have a latent state in the liver (hypnozoites)
with the ability to remain dormant for up to two years after primary infection [3]. P. ovale is suspected to
have a hypnozoite stage as well, however, the evidence for this is limited and controversial [6]. Both P. vivax
and P. ovale have reported relapse periods consistent with our patient’s presentation, however, P. ovale less
commonly produces clinical malaria and is more common in Africa than Asia [6,7]. P. vivax is not commonly
seen in Africa due to the lack of the Duffy antigen on erythrocytes in the region [2].
The classic episode of P. vivax infection begins with a prodrome of headache, anorexia, malaise, myalgias,
and gastrointestinal symptoms for one or more days followed by a remitting fever [2]. Subsequent
paroxysmal episodes occur in response to the rupturing of schizont-infected red blood cells (RBCs) [2]. These
episodes begin with a stage of chills and rigors that last for approximately one hour, followed by fevers
peaking 1-3 hours after rigors subside, and defervescence accompanied by diaphoresis and fatigue [2]. In
comparison to P. falciparum, P. vivax induces an inflammatory response at a significantly lower parasite load
[2]. Additionally, P. vivax has a predilection for reticulocytes, ultimately infecting < 2% of circulating
erythrocytes while maintaining a greater capacity of causing severe anemia than P. falciparum [2]. The
frequency of relapse depends on the infecting geographic strain of P. vivax [2]. Tropical strains relapse more
frequently, from 1-6 months, and temperate strains relapse at intervals of eight months or greater [2].
Clinical signs and abnormalities
D-dimer is often elevated during malarial infections [8]. P. falciparum is well known to cause adherence of
infected RBCs to the endothelium, causing damage and activation, and subsequently elevating D-dimer
levels [8]. P. vivax is reported to have the same effect albeit with a 10-fold lower capacity. D-dimer levels in-
turn reflect these pathophysiological differences [8].
In our case, our patient had a mild transaminitis and mild hyperbilirubinemia. Severe malarial infections can
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cause “malarial hepatopathy” which are defined by severe elevations of liver function tests [9]. These
serologic elevations are higher in P. falciparum than P. vivax infections, suggesting that the etiology is more
likely related to falciparum-specific etiologies (e.g. increased RBC cytoadherence) and not the presence of
hepatic hypnozoites in P. vivax [9,10]. Our patient did not meet the criteria for malarial hepatopathy. We
observed mild splenomegaly in our patient, a highly specific finding of malarial infection, and may simply
reflect normal splenic filtration of abnormal RBCs, vascular congestion due to malaria, and organ-specific
immune response against malaria [10,11].
On CT, our patient was found to have mild pulmonary edema and free peritoneal fluid. These findings are
rarely reported in non-severe malarial infections and consistent with the effects that malaria exerts on
endothelium and microvascular function [8,12].
Thrombocytopenia commonly occurs in malaria as well. The exact mechanism is not completely understood
but centers around immunologic mechanisms damaging thrombocytes and causing excess platelet removal
[13]. Thrombocytopenia is reported to have high sensitivity (94%), high specificity (73%), and a high
negative predictive value (97%) for malaria [14].
Diagnostic studies
Analysis of thick smear blood samples under light microscopy has greater sensitivity for diagnosing P.
falciparum than P. vivax due to P. vivax having a preference for infecting pre-circulating reticulocytes [3,15].
Serologic testing for lactate dehydrogenase (LDH) and aldolase is useful but requires a moderately elevated
parasitemia [3]. Antigen-detecting rapid diagnostic tests (RDTs) are now one of the most prevalent
diagnostic tools used worldwide reaching areas where microscopy and polymerase chain reaction (PCR) are
limited [16]. Overall, PCR testing tends to be the most sensitive as it is able to assess the presence of malaria,
even with low parasite counts [17]. We identified only one other report of malaria with negative PCR [18]. In
settings where laboratory testing is limited or high suspicion is not corroborated by diagnostic serologies (as
in our case), other clinical findings have consistently been shown to support a diagnosis of malaria. Positive
predictors include fever, non-pulsatile headache, chills and rigor, and periodicity to these symptoms [19,20].
Negative predictors include conjunctival suffusion, rash, respiratory rate >28, severe arthralgia/myalgia,
throat congestion, fever >40 C°, and continuous fever [19,20]. A previous study reports that among travelers
returning to the U.S, the most supportive clinical findings for malaria were splenomegaly, hepatomegaly,
hyperbilirubinemia, and thrombocytopenia [10]. From this case, additional predictors may include imaging
findings of non-specific fluid shifts (pulmonary edema, peritoneal fluid) reflecting malaria-induced
endothelial dysfunction and hepatic lymphadenopathy reflecting hepatic hypnozoite activity.
When the malaria species is unknown, the World Health Organization recommends treatment under the
assumed diagnosis of uncomplicated malaria by P. falciparum. This means that artemisinin-based
combination therapies should be primarily utilized, mainly for its ability to overcomes chloroquine-
resistance. If the patient has G6PD, treatment should be centered around primaquine. Additional treatment
with primaquine for 14 days in all transmission settings should be performed to prevent relapse [1].
Conclusions
Malaria is common and endemic to many countries outside of Africa (e.g. Asia), with P. vivax as the
predominating, causative species. PCR is the best test when suspicious for P. vivax, however, it is not always
diagnostic. Recurrence of febrile episodes maybe months to years apart. Clinical signs supportive of a
malarial infection are fever, rigors, chills, hepato/splenomegaly, hyperbilirubinemia, and
thrombocytopenia. Severe manifestations of malaria are life-threatening. G6PD should be tested for prior to
empiric treatment. When the malarial organism is unknown, treatment is approached as if the patient has an
uncomplicated P. falciparum infection.
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